What you should know:
1. PvP created TAK-062, also known as Kuma062, a drug that could potentially treat celiac disease by degrading undigested gluten.
2. The drug is the subject of a phase 1 study investigating TAK-062’s safety and tolerability in healthy patients and patients with celiac disease.
3. To acquire PvP, Takeda paid a negotiated upfront payment and could make additional payments of up to $330 million as the drug passes developmental and regulatory milestones.
4. Takeda and PvP previously entered into a strategic partnership, which granted Takeda acquisition rights in return for developmental funding.
More articles on surgery centers:
44% of U.S. physicians were employed by hospitals in 2018 + more market insights
Select Medical Holdings increases operating revenues 9.9% — 6 insights
Jury awards $1.6M to Iowa surgery center in anti-competition case
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
